| Title | Outcome and prognostic factors in metastatic urothelial carcinoma patients receiving second-line chemotherapy: an analysis of real-world clinical practice data in Japan |
|-------|----------------------------------------------------------------------------------------------------------|
| Author(s) | Matsumoto, Ryuji; Abe, Takashige; Ishizaki, Junji; Kikuchi, Hiroshi; Harabayashi, Toru; Minami, Keita; Sazawa, Ataru; Mochizuki, Tango; Akino, Tomoshige; Murakumo, Masashi; Osawa, Takahiro; Maruyama, Satoru; Murai, Sachiyo; Shinohara, Nobuo |
| Citation | Japanese journal of clinical oncology, 48(8), 771-776 |
| Issue Date | 2018-08 |
| Doc URL | http://hdl.handle.net/2115/72012 |
| Rights(URL) | http://creativecommons.org/licenses/by-nc/4.0/ |
| Type | article |
| Additional Information | There are other files related to this item in HUSCAP. Check the above URL. |
| File Information | hyy094.pdf |
Outcome and prognostic factors in metastatic urothelial carcinoma patients receiving second-line chemotherapy: an analysis of real-world clinical practice data in Japan

Ryuji Matsumoto¹, Takashige Abe¹,*, Junji Ishizaki², Hiroshi Kikuchi¹, Toru Harabayashi², Keita Minami², Ataru Sazawa², Tango Mochizuki², Tomoshige Akino², Masashi Murakumo², Takahiro Osawa¹, Satoru Maruyama¹, Sachiyu Murai¹, and Nobuo Shinohara¹

¹Department of Urology, Hokkaido University Graduate School of Medicine, and ²Hokkaido Urothelial Cancer Research Group, Sapporo, Japan

*For reprints and all correspondence: Abe Takashige, Department of Urology, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan. E-mail: takataka@rf6.so-net.ne.jp

Received 13 March 2018; Editorial Decision 2 June 2018; Accepted 13 June 2018

Abstract

Objectives: The objective of the present study was to investigate the survival outcome and prognostic factors of metastatic urothelial carcinoma patients treated with second-line systemic chemotherapy in real-world clinical practice.

Methods: Overall, 114 patients with metastatic urothelial carcinoma undergoing second-line systemic chemotherapy were included in this retrospective analysis. The dominant second-line chemotherapy was a paclitaxel-based combination regimen (60%, 68/114). We assessed the progression-free survival and overall survival times using the Kaplan–Meier method. The Cox proportional hazards model was applied to identify the factors affecting overall survival.

Results: The median progression-free survival and overall survival times were 4 and 9 months, respectively. In the multivariate analysis, an Eastern Cooperative Oncology Group performance status score greater than 0 at presentation, C-reactive protein level ≥1 mg/dl and poor response to prior chemotherapy were adverse prognostic indicators. Patients with 0, 1, 2 and 3 of those risk factors had a median overall survival of 17, 12, 7 and 3 months, respectively.

Conclusions: The Eastern Cooperative Oncology Group performance status at presentation, C-reactive protein level and response to prior chemotherapy were prognostic factors for metastatic urothelial carcinoma patients undergoing second-line chemotherapy. In the future, this information might help guide the choice of salvage treatment, such as second-line chemotherapy or immune checkpoint inhibitors, after the failure of first-line chemotherapy.

Key words: urothelial carcinoma, chemotherapy, second-line, metastatic
Introduction

Cisplatin-based combination chemotherapy has been the standard treatment for metastatic urothelial carcinoma (UC) patients. Although good initial response rates of approximately 50–70% to methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) or gemcitabine plus cisplatin (GC) have been reported, most patients subsequently become resistant to the first-line therapy, and salvage treatment remains a major challenge in daily clinical practice. To date, a growing body of literature has shown the safety and efficacy of second-line regimens for advanced and metastatic UC patients refractory to first-line chemotherapy, such as a paclitaxel-based salvage regimen (1–3). In Europe, based on the results of a phase III randomized trial showing the efficacy with a significant survival benefit of 2.5 months compared with best supportive care (4), vinflunine is also available as a treatment option, although it has yet to be approved in Japan. Several studies have evaluated prognostic factors in metastatic UC patients treated with second-line chemotherapy. Bellmunt et al. proposed a three-factor prognostic model consisting of the Eastern Cooperative Oncology Group performance status (ECOG PS), hemoglobin (Hb) level and liver metastasis (5). Thereafter, a duration from prior chemotherapy of shorter than 3 months and an albumin level below the lower limit of normal were also reported as adverse prognostic indicators (6,7). However, one of the potential limitations of those prognostic models is that, because they were constructed from phase II or III clinical trial data, where patients were strictly selected for study participation, there might be a gap compared with clinical practice in the real world. In the present study, using a retrospective database constructed from daily clinical practice at seven hospitals in Japan (8), we investigated prognostic factors in metastatic UC patients treated with second-line chemotherapy.

Patients and methods

Patients

The present multi-institutional study was performed with the approval of each institutional review board. We previously reported the outcome of a median overall survival (OS) of 17 months, derived from a total of 228 metastatic UC patients treated with systemic chemotherapy at Hokkaido University Hospital and six affiliated hospitals between 2000 and 2013 (8). Of the 228 patients, 122 undergoing second-line systemic chemotherapy were the subjects of the current study. After excluding 8 patients with missing data, 114 underwent further analysis. In the present study, we defined primary chemotherapy at the beginning of therapy for a metastatic lesion, so adjuvant or neoadjuvant therapy was not considered to be a platinum-based first-line chemotherapy.

Treatment methods

Our general treatment strategy for patients with metastatic UC was described previously (8). Briefly, regarding the first-line chemotherapy, early in the study period (2000–08), we used the MVAC regimen or its modification. After the GC regimen was approved for use in Japan in 2008, we chose that as the first-line chemotherapy regimen. In patients’ refractory or intolerant to the first-line chemotherapy, we considered second-line chemotherapy. The selection of the second-line regimen depended on each physician’s decision. Overall, the combination of paclitaxel, ifosfamide and nedaplatin (PIN) was the most frequently used regimen (57%, 65/114), because our group was conducting a phase II study of the PIN regimen for the early study period, and it became the most familiar salvage regimen among our group. In patients with a deteriorated renal function, we used the 24-h urinary creatinine clearance value to adjust the dose of chemotherapeutic agents. Our rules on dose modification of chemotherapeutic agents were previously reported (9). The objective response was evaluated by the treating physician according to the Response Evaluation Criteria in Solid Tumors, version 1.1, in most cases.

Data collection

Data were retrospectively collected from the patients’ medical charts, including the characteristics at the starting point of second-line chemotherapy, as described below. The progression-free survival (PFS) rate was calculated from the day when the second-line treatment was started to the date of radiological or clinical disease progression. The OS time was analyzed from the start of the second-line chemotherapy until death or the last follow-up examination.

Statistical analyses

The PFS and OS were estimated using the Kaplan–Meier method, and the log-rank test was used to assess the significance of differences. A proportional Cox hazard model was used to identify factors associated with the OS. Variables that were found to be significant in univariate analysis were selected for further evaluation in a multivariable model. We analyzed the following factors: age, sex, ECOG PS, primary site, pathology of the primary site, Hb level, neutrophil-to-lymphocyte ratio (NLR), platelet count, lactate dehydrogenase (LDH) level, C-reactive protein (CRP) level, albumin level, estimated glomerular filtration rate (eGFR), prior chemotherapy response, time since prior chemotherapy, visceral metastasis (lung, liver or bone) and liver metastasis. These were measured just before the start of the second-line chemotherapy. All statistical analyses were conducted using JMP Pro version 13.

P values <0.05 were considered significant.

Results

Patients’ characteristics

A summary of the patients’ characteristics is shown in Table 1. The median age at the start of the second-line chemotherapy was 65 years (range: 42–81 years). The ECOG PS score was 0 in 67 patients, 1 in 31 patients, 2 in 7 patients, 3 in 6 patients and unknown in 3 patients. Clinical records revealed that 10 patients (8.8%) had received adjuvant and/or neoadjuvant chemotherapy in the perioperative period. The primary site was resected at the initiation of first-line chemotherapy in 57 patients (50.0%). Regarding the metastatic site, 70 patients (61.4%) had lymph node metastasis, 44 (38.6%) had lung disease, 20 (17.5%) had bone disease, 18 (15.8%) had liver disease and 12 (10.5%) had local recurrence (there were overlapping cases). In terms of the first-line chemotherapy, 62 patients received the GC regimen, whereas MVAC or its modified regimen was given to 45 patients (Methotrexate, epirubicin, cisplatin: n = 37, Methotrexate, epirubicin, nedaplatin: n = 6, MVAC: n = 2). The median interval between the end of the first-line and beginning of the second-line treatment was 2 months (range: 1–74 months). In terms of the second-line chemotherapy, 68 (60%, 68/114) received paclitaxel-based combination regimens. The number of courses of first-line
and second-line chemotherapy in our cohort was a median of 4 (range: 1–14) and 3 (range: 1–17), respectively. Furthermore, 26 patients underwent third-line and 2 underwent forth-line chemotherapy, respectively.

### Survival outcomes and prognostic factors

Figure 1 shows PFS and OS curves for 114 patients. The median PFS and OS times were 4 and 9 months (95% confidence interval: 3.5–5 and 8–12), respectively (Fig. 1). Table 2 summarizes the responses to the second-line chemotherapy. The objective response rate was 28.1%, with a complete response (CR) in 8 patients (7.0%) and partial response (PR) in 24 (21.1%). The results of the uni and multivariate analyses of the prognostic characteristics at the time of the second-line chemotherapy starting point are shown in Table 3. In the univariate analysis, the ECOG PS, Hb level, NLR, platelet count, CRP level, albumin level, prior chemotherapy response and the presence of liver metastasis were significant predictors of OS. According to the multivariate analysis, the ECOG PS score at presentation, CRP level and prior chemotherapy response were significant independent predictors of prolonged OS. In addition, the ECOG PS score at presentation and CRP level were also significant independent predictors of prolonged PFS (Supplementary data, Table 1). We constructed a prognostic model that included these three independent prognostic factors. There were significant differences in OS among the four categories (Fig. 2). The median OS for patients with 0, 1, 2 and 3 risk factors was 17, 12, 7 and 3 months, respectively.

### Discussion

In the present study, based on a database retrospectively constructed from daily clinical practice at seven hospitals in Japan (8), we evaluated the outcome of salvage treatment for metastatic UC patients. Overall, the median PFS and OS times for metastatic UC patients who received second-line systemic chemotherapy were 4 and 9 months, respectively, being in line with previous results derived from several phase II and III studies (2,3,10,11). A multivariate model revealed that a good ECOG PS, CRP level <1 mg/dl and good response to prior chemotherapy were independent predictors

---

**Table 1. Patients’ characteristics**

| Characteristic | n = 114 |
|---------------|---------|
| Age, year     | median 65 (range, 42–81) |
| Sex male/female | Male 85 (74.6%) |
|               | Female 29 (25.4%) |
| ECOG performance status | 0 67 (58.8%) |
|               | 1 31 (27.2%) |
|               | 2 7 (6.1%) |
|               | 3 6 (5.3%) |
|               | Unknown 3 (2.6%) |
| Primary site   | Bladder 49 (43.0%) |
|               | Upper urinary tract 53 (48.2%) |
|               | Both 6 (5.3%) |
|               | Urethra/prostate 4 (3.5%) |
| Adjuvant and/or neoadjuvant chemotherapy | Yes 10 (8.8%) |
|               | No 104 (91.2%) |
| Pathology of primary site | Pure UC 83 (72.8%) |
|               | Others 20 (17.5%) |
|               | Cytology positive 11 (9.6%) |
| Baseline laboratory data | Hemoglobin, g/dl (n = 114) median 10.6 (range, 7.1–17.8) |
|               | NLR (n = 99) median 3.09 (range, 0.37–46.5) |
|               | Platelets (n = 114) median 23 (range, 9–83.4) |
|               | LDH, IU/l (n = 114) median 202 (range, 113–1034) |
|               | CRP, mg/dl (n = 113) median 0.51 (range, 0.01–17.26) |
|               | Albumin, g/dl (n = 108) median 3.8 (range, 2.2–4.7) |
|               | eGFR, ml/min/1.73 m² (n = 114) median 48.2 (range, 21.8–124.5) |
|               | FIT (n, 4 ml/min/1.73 m²) median 29 (range, 0.7–124.5) |
|               | Cisplatin-unfit (<60 ml/min/1.73 m²) median 85 (range, 7–124.5) |
| Metastatic site | Lymph node 70 (61.4%) |
|               | Lung 44 (38.6%) |
|               | Bone 20 (17.5%) |
|               | Liver 18 (15.8%) |
|               | Local recurrence 12 (10.5%) |
| Prior chemotherapy | GC 62 (54.4%) |
|               | Gemcitabine, carboplatin 2 (1.8%) |
|               | MEC 37 (32.5%) |
|               | Methotrexate, etoposide, nedaplatin 6 (5.3%) |
|               | MVAC 2 (1.8%) |
|               | PIN 5 (4.4%) |
| Response to first-line chemotherapy | CR 9 (7.9%) |
|               | PR 49 (43.0%) |
|               | SD 25 (21.9%) |
|               | PD 30 (26.3%) |
|               | Not evaluable 1 (0.9%) |
| Time from prior chemotherapy, months | median 2 (range, 1–71) |
| Second-line regimens | PIN 65 (57.0%) |
|               | Gemcitabine, carboplatin 15 (13.2%) |

**Table 1. Continued**

| Characteristic | n = 114 |
|---------------|---------|
| GC            | 15 (13.2%) |
| Gemcitabine   | 8 (7.0%) |
| MEC           | 4 (3.5%) |
| Methotrexate, etoposide, nedaplatin | 2 (1.8%) |
| Paclitaxel, carboplatin | 2 (1.8%) |
| Gemcitabine, docetaxel | 1 (0.9%) |
| Gemcitabine, nedaplatin | 1 (0.9%) |
| Gemcitabine, paclitaxel | 1 (0.9%) |

eGFR, estimated glomerular filtration rate; CR, complete response; CRP, C-reactive protein; LDH, lactate dehydrogenase; MEC, methotrexate, etoposide and nedaplatin; MVAC, methotrexate, vinblastine, doxorubicin and cisplatin; NE, not evaluable; NLR, neutrophil-to-lymphocyte ratio; PD, progressive disease; PIN, paclitaxel, ifosphamide and nedaplatin; PR, partial response; SD, stable disease; UC, urothelial carcinoma.
of prolonged OS. In terms of the survival impact of ECOG PS, our observations were in line with previous studies; using a pooled database built from several phase II or III clinical trials of second-line chemotherapy for metastatic UC, Bellumunt et al. and Sonpavde et al. observed that a PS score >0 was a significant prognostic factor affecting OS (5–7).

Several researchers have reported the survival impact of CRP in various cancers, including lower or upper UC after extirpative surgery (12–14). Saito et al. reported that baseline and nadir CRP levels and CRP kinetics status were significantly correlated with the prognosis of advanced or metastatic UC patients who had received gemcitabine, etoposide and cisplatin as second-line chemotherapy (14). Furthermore, Ishioka et al., in a total of 223 patients with advanced or metastatic UC, noted that CRP was a continuously significant prognostic factor for OS, and the predictive accuracy of a survival nomogram that they developed was improved by adding CRP, although around 40% of their cohort were treated solely by best supportive care (15). Our observation that a CRP level <1 mg/dl was an independent predictor of prolonged OS, further supported its importance in the treatment of metastatic UC patients.

Regarding the prognostic impact of the response to prior chemotherapy, we observed that a good response (CR and PR) to the first-line chemotherapy was associated with the survival outcomes after salvage treatments. Previously, Pond et al. reported in their pooled patients with advanced UC undergoing second-line chemotherapy, collected from six phase II trials, that the objective responses (PR and CR) to previous chemotherapy did not confer an independent prognostic effect with second-line therapy (16), in contrast to our observation. However, they reported that, when examining the response to prior chemotherapy as stable disease or better as compared with others, a borderline significant correlation ($P = 0.05$) with OS was detected. In the present cohort, we also observed that a relatively good response (CR, PR and SD) to the first-line chemotherapy was associated with the survival outcomes (data not shown). As shown in Table 1, a combination of PIN was the most frequently used regimen (57%, 65/114), because our group was conducting a phase II study of the PIN regimen for the early study period (1), which made the PIN regimen the most familiar option among our group. In another phase II study of PIN regimen, Kitamura et al. reported that patients with a CR or PR after the first-line chemotherapy showed a good response to PIN (2). Taken together with the possibility of cross-resistance to chemotherapeutic agents, for example, between cisplatin and a cisplatin-analog, we believe that a good response to previous chemotherapy could reflect good survival outcomes after second-line chemotherapy, although our observations need to be confirmed in a larger cohort.

Recently, immune checkpoint inhibitors (ICIs) such as programmed death-ligand 1 (PD-L1) and programmed cell death protein 1 (PD-1) checkpoints were developed as efficacious antitumor drugs for patients with advanced or metastatic UC, mainly in those whose disease has progressed after first-line platinum-containing chemotherapy (17–21). For example, atezolizumab, a PD-L1 inhibitor, led to an objective response rate of 15% and median OS time of 7.9 months in a multicenter phase II trial (17). Pembrolizumab, a PD-1 inhibitor, was correlated with a significantly longer OS time (10.3 vs. 7.4 months, respectively, hazard ratio for death $= 0.73$, $P = 0.002$) and a lower rate of adverse events than chemotherapy as a second-line therapy for platinum-refractory, advanced UC in an international phase III trial (18). Very recently, Szabados et al. reported a very interesting study evaluating the response to systemic chemotherapy after ICIs (22). They collected two cohorts undergoing sequential treatments for metastatic UC. Cohort A ($n = 14$) received ICIs initially followed by systemic chemotherapy after disease progression, and cohort B ($n = 14$) received salvage chemotherapy after the failure of first-line chemotherapy followed by ICIs. The best response rate to chemotherapy after ICIs was 64% for cohort A and 21% for cohort B, which were the same response rates to first-line or second-line chemotherapy previously reported in the pre-ICI era.

Although ICIs probably change the landscape in the treatment of advanced UC, we consider that salvage chemotherapy still remains an important treatment option. The prognostic factors and survival model we built in the present study might be applicable for patient stratification in the future. However, we do not have clear answers.
regarding whether patients with adverse characteristics should be treated by ICI first after the failure of first-line chemotherapy. We need to accumulate more experiences, especially cases treated by ICI.

Our analysis was limited by its retrospective nature and small sample size. We could not come to a conclusion regarding the appropriate chemotherapy regimen that should be used in a salvage setting due to the heterogeneity of our cohort, although the efficacy of combination chemotherapy comparing to that of single-agent use might be superior according to a recent review (23). Furthermore, as an important limitation, the dominant second-line chemotherapy regimen in the present study was PIN, which is not widely utilized outside of Japan. Assessment of the radiological response might not be as strict as that in prospective clinical studies. It is unknown whether the prognostic factors identified in this analysis are applicable in the new era of ICIs, and we need to accumulate experience and reassess that in the future. Nevertheless, we believe that several important findings were generated by the current analyses.

### Table 3. Univariate and multivariate analyses of the prognostic characteristics at the time of the second-line chemotherapy start point

| Characteristic                        | No. of patients | Median survival, months (95% CI) | P value | Hazard ratio (95% CI) | P value |
|--------------------------------------|-----------------|----------------------------------|---------|-----------------------|---------|
| Age, year                            |                 |                                  |         |                       |         |
| ≥65                                  | 62              | 8 (6–11)                         | 0.0769  |                       |         |
| <65                                  | 52              | 10.5 (8–15)                      |         |                       |         |
| Sex male/female                      |                 |                                  |         |                       |         |
| Male                                 | 85              | 9 (7–11)                         | 0.1956  |                       |         |
| Female                               | 29              | 12 (6–23)                        |         |                       |         |
| Performance status                   |                 |                                  |         |                       |         |
| ≥1                                   | 44              | 5.5 (4–8)                        | <0.0001 | 2.460 (1.437–4.191)   | 0.0011  |
| 0                                    | 67              | 13 (9–19)                        |         |                       |         |
| Primary site                         |                 |                                  |         |                       |         |
| Bladder only                         | 49              | 10 (8–15)                        | 0.4721  |                       |         |
| Others                               | 65              | 9 (6–12)                         |         |                       |         |
| Pathology of primary site            |                 |                                  |         |                       |         |
| Pure UC                              | 83              | 10 (8–15)                        | 0.1457  |                       |         |
| Others                               | 20              | 7 (4–14)                         |         |                       |         |
| Hb                                   |                 |                                  |         |                       |         |
| <10 g/dl                             | 41              | 8 (5–9)                          | 0.0145  | 1.038 (0.563–1.679)   | 0.8927  |
| ≥10 g/dl                             | 73              | 12 (8–15)                        |         |                       |         |
| NLR                                  |                 |                                  |         |                       |         |
| ≥3                                   | 55              | 7 (5–9)                          | 0.0005  | 1.102 (0.539–1.529)   | 0.7134  |
| <3                                   | 44              | 15 (11–21)                       |         |                       |         |
| Platelets                            |                 |                                  |         |                       |         |
| <20 × 10^4/μl                        | 35              | 12 (8–20)                        | 0.0354  | 0.998 (0.593–1.663)   | 0.995   |
| ≥20 × 10^4/μl                        | 79              | 8 (6–11)                         |         |                       |         |
| LDH                                  |                 |                                  |         |                       |         |
| ≥200                                 | 62              | 8.5 (7–11)                       | 0.2027  |                       |         |
| <200                                 | 52              | 11 (8–15)                        |         |                       |         |
| CRP                                  |                 |                                  |         |                       |         |
| ≥1                                   | 39              | 5 (3–7)                          | <0.0001 | 2.631 (1.434–4.762)   | 0.002   |
| <1                                   | 74              | 13 (11–16)                       |         |                       |         |
| Albumin                              |                 |                                  |         |                       |         |
| ≥4.0                                 | 43              | 15 (11–21)                       | 0.0002  | 0.800 (0.465–1.394)   | 0.4264  |
| <4.0                                 | 65              | 8 (5–9)                          |         |                       |         |
| eGFR                                 |                 |                                  |         |                       |         |
| Fit                                  | 29              | 10 (5–15)                        | 0.7114  |                       |         |
| CsPi-unfit                           | 85              | 9 (7–12)                         |         |                       |         |
| Prior chemotherapy response          |                 |                                  |         |                       |         |
| SD or PD                             | 55              | 7 (5–8)                          | 0.0002  | 1.839 (1.132–2.973)   | 0.0141  |
| PR or CR                             | 58              | 12 (9–16)                        |         |                       |         |
| Time from prior chemotherapy         |                 |                                  |         |                       |         |
| ≥3 Months                            | 42              | 12 (8–17)                        | 0.129   |                       |         |
| <3 Months                            | 72              | 8 (7–11)                         |         |                       |         |
| Visceral metastasis (lung, liver or bone) |         |                                  |         |                       |         |
| Yes                                  | 63              | 9 (7–12)                         | 0.6245  |                       |         |
| No                                   | 51              | 10 (7–14)                        |         |                       |         |
| Liver metastasis                     |                 |                                  |         |                       |         |
| Yes                                  | 18              | 6.5 (3–8)                        | 0.0444  | 1.479 (0.739–2.770)   | 0.2568  |
| No                                   | 96              | 10 (9–12)                        |         |                       |         |

Hb, hemoglobin; CI, confidence interval.
Second-line chemotherapy for metastatic UC

Conclusions
The ECOG PS at presentation, CRP level and response to prior chemotherapy were prognostic factors for metastatic UC patients undergoing second-line chemotherapy in real-world clinical practice. In the future, this information might provide additional clues to aid in the choice of salvage treatment, such as second-line chemotherapy or the use of ICIs after the failure of first-line chemotherapy.

Supplementary data
Supplementary data are available at *Japanese Journal of Clinical Oncology* online.

Funding
There were no financial supports for this study.

Conflict of interest statement
There are no competing financial interests related to this study.

References
1. Shimohara N, Harabayashi T, Suzuki S, et al. Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy. *Cancer Chemother Pharmacol* 2006;58:402–7.
2. Kitamura H, Taguchi K, Kunishima Y, et al. Paclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: a phase II study of the SUOC group. *Cancer Sci* 2011;102:1171–5.
3. Kobayashi K, Matsuura H, Shimizu K, et al. Clinical significance of a second-line chemotherapy regimen with paclitaxel, ifosfamide and nedaplatin for metastatic urothelial carcinoma after failure of cisplatin-based chemotherapy. *Int J Clin Oncol* 2016;21:775–80.
4. Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. *J Clin Oncol* 2009;27:4454–61.
5. Bellmunt J, Choueiri TK, Fougerey R, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. *J Clin Oncol* 2010;28:1850–5.
6. Sonpavde G, Pond GR, Fougerey R, et al. Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. *Eur Urol* 2013;63:717–23.
7. Sonpavde G, Pond GR, Rosenberg JE, et al. Improved 5-factor prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma. *J Urol* 2016;195:277–82.
8. Abe T, Ishizaki J, Kikuchi H, et al. Outcome of metastatic urothelial carcinoma treated by systemic chemotherapy: prognostic factors based on real-world clinical practice in Japan. *Urol Oncol* 2017;35:e1–38.
9. Maru S, Abe T, Shimohara N, et al. Influence of baseline renal function and dose reduction of nephrotoxic chemotherapeutic agents on the outcome of metastatic urothelial carcinoma: a retrospective study. *Int J Urol* 2012;19:110–6.
10. Vaughn DJ, Srinivas S, Stadler WM, et al. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. *Cancer* 2009;115:4110–7.
11. Albers P, Park SI, Niegsch G, et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AOU) trial AB 2099]. *Ann Oncol* 2011;22:288–94.
12. Grimm T, Buchner A, Schneebö B, et al. Impact of preoperative hemo-globin and CRP levels on cancer-specific survival in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: results of a single-center study. *World J Urol* 2016;34:703–8.
13. Tanaka N, Kikuchi E, Shrotake S, et al. The predictive value of C-reactive protein for prognosis in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy: a multi-institutional study. *Eur Urol* 2014;65:227–34.
14. Saito K, Urakami S, Komai Y, et al. Impact of C-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chemotherapy with gemcitabine, etoposide and cisplatin. *BJU Int* 2012;110:1478–84.
15. Iishioka J, Saito K, Sakura M, et al. Development of a nomogram incorpor-ating serum C-reactive protein level to predict overall survival of patients with advanced urothelial carcinoma and its evaluation by decision curve analysis. *Br J Cancer* 2012;107:1031–6.
16. Pond GR, Bellmunt J, Fougerey R, et al. Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. *Clin Genitourin Cancer* 2013;11:495–500.
17. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. *Lancet* 2016;387:1909–20.
18. Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. *N Engl J Med* 2017;376:1013–26.
19. Sharma P, Callahan MK, Bono P, et al. Nivolumab monotherapy in recur rent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. *Lancet Oncol* 2016;17:1590–9.
20. Powles T, O’Donnell PH, Massard C, et al. Efficacy and safety of durva-lumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. *JAMA Oncol* 2017;3:e172411.
21. Apolo AB, Infante JR, Balmanoukian A, et al. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory meta static urothelial carcinoma: results from a multicenter, phase Ib study, *J Clin Oncol* 2017;35:2117–24.
22. Szabados B, van Dijk N, Tang YZ, et al. Response rate to chemotherapy after immune checkpoint inhibition in metastatic urothelial cancer. *Eur Urol* 2018;73:149–52.
23. Sonpavde G, Pond GR, Choueiri TK, et al. Single-agent taxane versus taxane-containing combination chemotherapy as salvage therapy for advanced urothelial carcinoma. *Eur Urol* 2016;69:634–41.